A neutralizing antibody against receptor for advanced glycation end products (RAGE) reduces atherosclerosis in uremic mice

Susanne Bro, Allan Flyvbjerg, Christoph J. Binder, Christian A. Bang, Larry Denner, Klaus Olgaard, Lars B. Nielsen

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Chronic renal failure markedly accelerates atherogenesis in apolipoprotein E-deficient (apoE-/-) mice. To study the putative role of receptor for advanced glycation end products (RAGE) in development of uremic atherosclerosis, apoE-/- mice received intraperitoneal injections thrice weekly of a neutralizing murine RAGE-antibody (RAGE-ab) (n = 21) or an isotype-matched control antibody (placebo-ab) (n = 23). Treatment was started 4 weeks after surgical 5/6 nephrectomy in 16 weeks old mice and continued for 12 weeks. The RAGE-ab did not affect blood pressure, plasma cholesterol or measures of uremia. However, the aortic plaque area fraction was reduced by 59% in RAGE-ab compared with placebo-ab-treated mice (0.016 ± 0.002 versus 0.039 ± 0.005, P < 0.001). In plasma, the RAGE-ab reduced concentrations of oxidized phospholipid neo-epitopes in plasma as detected by the specific monoclonal antibody EO6 (P < 0.05) and titers of IgG antibodies against oxidized low-density lipoprotein (P < 0.001). In the aorta of treated mice, the RAGE-ab did not affect the mRNA expression of eight selected genes associated with inflammation. The results suggest that blockade of RAGE reduces the proatherogenic effects of uremia, possibly through a systemic decrease in oxidative stress.

Original languageEnglish (US)
Pages (from-to)274-280
Number of pages7
JournalAtherosclerosis
Volume201
Issue number2
DOIs
StatePublished - Dec 2008

Fingerprint

Neutralizing Antibodies
Atherosclerosis
Uremia
Apolipoproteins E
Antibodies
Placebos
Intraperitoneal Injections
Nephrectomy
Chronic Kidney Failure
Aorta
Advanced Glycosylation End Product-Specific Receptor
Epitopes
Phospholipids
Oxidative Stress
Immunoglobulin G
Cholesterol
Monoclonal Antibodies
Blood Pressure
Inflammation
Messenger RNA

Keywords

  • Antibodies against oxidized low density lipoprotein
  • Atherosclerosis
  • EO6
  • ICAM-1
  • Oxidized phospholipid neo-epitopes
  • Receptor for advanced glycation end products
  • Renal failure
  • VCAM-1

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

A neutralizing antibody against receptor for advanced glycation end products (RAGE) reduces atherosclerosis in uremic mice. / Bro, Susanne; Flyvbjerg, Allan; Binder, Christoph J.; Bang, Christian A.; Denner, Larry; Olgaard, Klaus; Nielsen, Lars B.

In: Atherosclerosis, Vol. 201, No. 2, 12.2008, p. 274-280.

Research output: Contribution to journalArticle

Bro, Susanne ; Flyvbjerg, Allan ; Binder, Christoph J. ; Bang, Christian A. ; Denner, Larry ; Olgaard, Klaus ; Nielsen, Lars B. / A neutralizing antibody against receptor for advanced glycation end products (RAGE) reduces atherosclerosis in uremic mice. In: Atherosclerosis. 2008 ; Vol. 201, No. 2. pp. 274-280.
@article{451606ccbcee420b8321264d52d8ee26,
title = "A neutralizing antibody against receptor for advanced glycation end products (RAGE) reduces atherosclerosis in uremic mice",
abstract = "Chronic renal failure markedly accelerates atherogenesis in apolipoprotein E-deficient (apoE-/-) mice. To study the putative role of receptor for advanced glycation end products (RAGE) in development of uremic atherosclerosis, apoE-/- mice received intraperitoneal injections thrice weekly of a neutralizing murine RAGE-antibody (RAGE-ab) (n = 21) or an isotype-matched control antibody (placebo-ab) (n = 23). Treatment was started 4 weeks after surgical 5/6 nephrectomy in 16 weeks old mice and continued for 12 weeks. The RAGE-ab did not affect blood pressure, plasma cholesterol or measures of uremia. However, the aortic plaque area fraction was reduced by 59{\%} in RAGE-ab compared with placebo-ab-treated mice (0.016 ± 0.002 versus 0.039 ± 0.005, P < 0.001). In plasma, the RAGE-ab reduced concentrations of oxidized phospholipid neo-epitopes in plasma as detected by the specific monoclonal antibody EO6 (P < 0.05) and titers of IgG antibodies against oxidized low-density lipoprotein (P < 0.001). In the aorta of treated mice, the RAGE-ab did not affect the mRNA expression of eight selected genes associated with inflammation. The results suggest that blockade of RAGE reduces the proatherogenic effects of uremia, possibly through a systemic decrease in oxidative stress.",
keywords = "Antibodies against oxidized low density lipoprotein, Atherosclerosis, EO6, ICAM-1, Oxidized phospholipid neo-epitopes, Receptor for advanced glycation end products, Renal failure, VCAM-1",
author = "Susanne Bro and Allan Flyvbjerg and Binder, {Christoph J.} and Bang, {Christian A.} and Larry Denner and Klaus Olgaard and Nielsen, {Lars B.}",
year = "2008",
month = "12",
doi = "10.1016/j.atherosclerosis.2008.01.015",
language = "English (US)",
volume = "201",
pages = "274--280",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - A neutralizing antibody against receptor for advanced glycation end products (RAGE) reduces atherosclerosis in uremic mice

AU - Bro, Susanne

AU - Flyvbjerg, Allan

AU - Binder, Christoph J.

AU - Bang, Christian A.

AU - Denner, Larry

AU - Olgaard, Klaus

AU - Nielsen, Lars B.

PY - 2008/12

Y1 - 2008/12

N2 - Chronic renal failure markedly accelerates atherogenesis in apolipoprotein E-deficient (apoE-/-) mice. To study the putative role of receptor for advanced glycation end products (RAGE) in development of uremic atherosclerosis, apoE-/- mice received intraperitoneal injections thrice weekly of a neutralizing murine RAGE-antibody (RAGE-ab) (n = 21) or an isotype-matched control antibody (placebo-ab) (n = 23). Treatment was started 4 weeks after surgical 5/6 nephrectomy in 16 weeks old mice and continued for 12 weeks. The RAGE-ab did not affect blood pressure, plasma cholesterol or measures of uremia. However, the aortic plaque area fraction was reduced by 59% in RAGE-ab compared with placebo-ab-treated mice (0.016 ± 0.002 versus 0.039 ± 0.005, P < 0.001). In plasma, the RAGE-ab reduced concentrations of oxidized phospholipid neo-epitopes in plasma as detected by the specific monoclonal antibody EO6 (P < 0.05) and titers of IgG antibodies against oxidized low-density lipoprotein (P < 0.001). In the aorta of treated mice, the RAGE-ab did not affect the mRNA expression of eight selected genes associated with inflammation. The results suggest that blockade of RAGE reduces the proatherogenic effects of uremia, possibly through a systemic decrease in oxidative stress.

AB - Chronic renal failure markedly accelerates atherogenesis in apolipoprotein E-deficient (apoE-/-) mice. To study the putative role of receptor for advanced glycation end products (RAGE) in development of uremic atherosclerosis, apoE-/- mice received intraperitoneal injections thrice weekly of a neutralizing murine RAGE-antibody (RAGE-ab) (n = 21) or an isotype-matched control antibody (placebo-ab) (n = 23). Treatment was started 4 weeks after surgical 5/6 nephrectomy in 16 weeks old mice and continued for 12 weeks. The RAGE-ab did not affect blood pressure, plasma cholesterol or measures of uremia. However, the aortic plaque area fraction was reduced by 59% in RAGE-ab compared with placebo-ab-treated mice (0.016 ± 0.002 versus 0.039 ± 0.005, P < 0.001). In plasma, the RAGE-ab reduced concentrations of oxidized phospholipid neo-epitopes in plasma as detected by the specific monoclonal antibody EO6 (P < 0.05) and titers of IgG antibodies against oxidized low-density lipoprotein (P < 0.001). In the aorta of treated mice, the RAGE-ab did not affect the mRNA expression of eight selected genes associated with inflammation. The results suggest that blockade of RAGE reduces the proatherogenic effects of uremia, possibly through a systemic decrease in oxidative stress.

KW - Antibodies against oxidized low density lipoprotein

KW - Atherosclerosis

KW - EO6

KW - ICAM-1

KW - Oxidized phospholipid neo-epitopes

KW - Receptor for advanced glycation end products

KW - Renal failure

KW - VCAM-1

UR - http://www.scopus.com/inward/record.url?scp=56649083783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56649083783&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2008.01.015

DO - 10.1016/j.atherosclerosis.2008.01.015

M3 - Article

VL - 201

SP - 274

EP - 280

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -